(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 202.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,205.54%.
An2 Therapeutics's earnings in 2026 is -$33,986,000.On average, 3 Wall Street analysts forecast ANTX's earnings for 2026 to be -$25,434,559, with the lowest ANTX earnings forecast at -$24,437,125, and the highest ANTX earnings forecast at -$26,182,634.
In 2027, ANTX is forecast to generate -$22,360,052 in earnings, with the lowest earnings forecast at -$21,483,187 and the highest earnings forecast at -$23,017,700.